JP2022510410A5 - - Google Patents

Info

Publication number
JP2022510410A5
JP2022510410A5 JP2021531722A JP2021531722A JP2022510410A5 JP 2022510410 A5 JP2022510410 A5 JP 2022510410A5 JP 2021531722 A JP2021531722 A JP 2021531722A JP 2021531722 A JP2021531722 A JP 2021531722A JP 2022510410 A5 JP2022510410 A5 JP 2022510410A5
Authority
JP
Japan
Prior art keywords
compound
item
composition according
subject
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021531722A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022510410A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/065069 external-priority patent/WO2020118252A1/en
Publication of JP2022510410A publication Critical patent/JP2022510410A/ja
Publication of JP2022510410A5 publication Critical patent/JP2022510410A5/ja
Pending legal-status Critical Current

Links

JP2021531722A 2018-12-07 2019-12-06 去勢抵抗性および去勢感受性前立腺がんを処置するための方法 Pending JP2022510410A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862776985P 2018-12-07 2018-12-07
US62/776,985 2018-12-07
US201962909147P 2019-10-01 2019-10-01
US62/909,147 2019-10-01
US201962926390P 2019-10-25 2019-10-25
US62/926,390 2019-10-25
PCT/US2019/065069 WO2020118252A1 (en) 2018-12-07 2019-12-06 Methods for treating castration-resistant and castration- sensitive prostate cancer

Publications (2)

Publication Number Publication Date
JP2022510410A JP2022510410A (ja) 2022-01-26
JP2022510410A5 true JP2022510410A5 (cg-RX-API-DMAC7.html) 2022-11-29

Family

ID=70974424

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021531722A Pending JP2022510410A (ja) 2018-12-07 2019-12-06 去勢抵抗性および去勢感受性前立腺がんを処置するための方法

Country Status (9)

Country Link
US (2) US20200281949A1 (cg-RX-API-DMAC7.html)
EP (1) EP3891294A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022510410A (cg-RX-API-DMAC7.html)
KR (1) KR20210100145A (cg-RX-API-DMAC7.html)
CN (1) CN113164500A (cg-RX-API-DMAC7.html)
AU (1) AU2019395100A1 (cg-RX-API-DMAC7.html)
CA (1) CA3120850A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021005075A (cg-RX-API-DMAC7.html)
WO (1) WO2020118252A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10471023B2 (en) 2015-03-12 2019-11-12 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
HUE045585T2 (hu) 2015-05-18 2020-01-28 Tolero Pharmaceuticals Inc Megnövelt biológiai hozzáférhetõséggel rendelkezõ Alvocidib gyógyszer-elõanyagok
US20170298033A1 (en) 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー, インコーポレイテッド Mcl-1阻害剤アルボシジブを用いた、bcl-2阻害剤に対して非感受性である癌の治療レジメン
US20190240198A1 (en) * 2018-02-05 2019-08-08 Dean G. Tang Formulations and methods for the treatment of cancers
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置
US12109179B2 (en) 2019-03-28 2024-10-08 Essa Pharma Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
EP4135675A4 (en) 2020-04-17 2024-04-10 Essa Pharma, Inc. SOLID FORMS OF AN N-TERMINAL DOMAIN ANDROGEN RECEPTOR INHIBITOR AND USES THEREOF
CA3215182A1 (en) * 2021-04-16 2022-10-20 Han-Jie Zhou Pharmaceutical compositions comprising inhibitors of the androgen receptor and uses thereof
WO2023114264A1 (en) * 2021-12-15 2023-06-22 Eli Lilly And Company Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001253618A1 (en) * 2000-04-21 2001-11-07 Arch Development Corporation Flavopiridol drug combinations and methods with reduced side effects
HK1212683A1 (zh) * 2012-09-26 2016-06-17 Mannkind Corporation 多个激酶途径抑制剂
EP2945628B1 (en) * 2013-01-15 2020-04-15 Aragon Pharmaceuticals, Inc. Androgen receptor modulator in combination with abiraterone acetate and prednisone for treating prostate cancer
WO2016033114A1 (en) * 2014-08-25 2016-03-03 The Johns Hopkins University Methods and compositions related to prostate cancer therapeutics
HUE045585T2 (hu) * 2015-05-18 2020-01-28 Tolero Pharmaceuticals Inc Megnövelt biológiai hozzáférhetõséggel rendelkezõ Alvocidib gyógyszer-elõanyagok
WO2018094275A1 (en) * 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
US11034710B2 (en) * 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer

Similar Documents

Publication Publication Date Title
Markman Managing taxane toxicities
RU2587013C2 (ru) Комбинированная химиотерапия
JP2019529581A5 (cg-RX-API-DMAC7.html)
JP2020516646A5 (cg-RX-API-DMAC7.html)
JP2020517696A5 (cg-RX-API-DMAC7.html)
JP2012522837A5 (cg-RX-API-DMAC7.html)
CN115025090A (zh) 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒
JP2009536956A (ja) 抗癌治療法
CN117881396A (zh) 用螺甾内酯和酰基富烯的组合治疗癌症
JP2020536055A5 (cg-RX-API-DMAC7.html)
WO2020051294A1 (en) The combination of xpo1 inhibitors and second agents for the treatment of prostate cancer
KR20240006610A (ko) 다중-키나제 억제제의 제약 조성물 및 용도
JP2023509191A (ja) 癌を治療するための組み合わせ療法
JP2025511402A5 (cg-RX-API-DMAC7.html)
Hainsworth et al. Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinoma
CA2525277A1 (en) Method for augmenting the antitumor activity of anti-cancer agents
JPH1045589A (ja) テモゾロミドによる改良されたガンの処置
JP2020517739A (ja) リンパ節陽性の初期ホルモン受容体陽性かつヒト上皮成長因子受容体2陰性乳癌の補助治療のための内分泌療法とアベマシクリブとの組み合わせ
Köppler et al. Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions
JP2024523123A (ja) 去勢抵抗性前立腺がんの治療薬の調製におけるスタキオースの使用
AU2024334390A1 (en) Anti-tumor use of act001 composition
JP2025511403A5 (cg-RX-API-DMAC7.html)
WO2022165056A1 (en) Treating cancer in patient with pten inactivating mutation
KR20240046527A (ko) 암치료를 위한 신규 경구용 약학적 조성물
JPH09506902A (ja) 前立線癌の化学療法剤の補助剤